Approvals
InnoCare receives clearance for leukaemia/lymphoma trial in China
The safety and efficacy of ICP-248 plus orelabrutinib against immunochemotherapy will be assessed in the trial.
The safety and efficacy of ICP-248 plus orelabrutinib against immunochemotherapy will be assessed in the trial.